- All efficacy endpoints were comparable during long-term treatment in the maintenance and switch groups20
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
ҩ Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ± 15%18.
ɣ Primary endpoint.
# ITT population
RA, Rheumatoid Arthritis; CI, Confidence interval; ITT, Intention-to-treat; PP, Per-protocol.
PP-IFA-GBR-0288. December 2018